Literature DB >> 3053457

The effects of infection prevention regimens on early infectious complications in marrow transplant patients: a four arm randomized study.

F Petersen1, M Thornquist, C Buckner, G Counts, N Nelson, J Meyers, R Clift, E Thomas.   

Abstract

Three hundred and forty-two patients with hematological malignancies underwent allogeneic marrow transplantation from family donors and were allocated to receive 1) no specific infection prophylaxis in a conventional hospital room (control, 100 patients), 2) prophylactic systemic antibiotics (PSA) in a conventional hospital room (PSA group, 101 patients), 3) decontamination and isolation in a laminar air flow (LAF) room (LAF group, 65 patients) and 4) PSA in an LAF room (LAF+PSA group, 76 patients). Patients were studied for bacterial and fungal complications from the day of admission and until engraftment. LAF isolation was discontinued before engraftment in 27% (LAF+PSA group) to 32% (LAF group) of isolated in 26% (LAF+PSA group) to 27% (PSA group) of patients on prophylactic antibiotics. Septicemia occurred in 41%, 22%, 25% and 10% of patients in the control, PSA, LAF and LAF+PSA group, respectively. The incidence of septicemia was significantly less in the LAF+PSA group than in the control and LAF group with the incidence of septicemia significantly higher in the control group than in any of the other three groups. No other risk factors analyzed in proportional hazards regression tests were associated with septicemia acquisition. It is concluded that effective infection prevention modalities significantly reduce infection morbidity in transplant patients. Since most granulocytopenic transplant patients not receiving PSA will receive empiric or therapeutic broad spectrum antibiotics. The use of PSA in or out of LAF isolation is recommended as an effective modality to reduce septicemia acquisition.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3053457     DOI: 10.1007/BF01650752

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  25 in total

Review 1.  Bone-marrow transplantation (first of two parts).

Authors:  E Thomas; R Storb; R A Clift; A Fefer; F L Johnson; P E Neiman; K G Lerner; H Glucksberg; C D Buckner
Journal:  N Engl J Med       Date:  1975-04-17       Impact factor: 91.245

2.  Laminar air flow isolation and decontamination: a prospective randomized study of the effects of prophylactic systemic antibiotics in bone marrow transplant patients.

Authors:  F B Petersen; C D Buckner; R A Clift; S Lee; N Nelson; G W Counts; J D Meyers; J E Sanders; P S Stewart; W I Bensinger
Journal:  Infection       Date:  1986 May-Jun       Impact factor: 3.553

Review 3.  Infections in bone marrow transplant recipients.

Authors:  D Engelhard; M I Marks; R A Good
Journal:  J Pediatr       Date:  1986-03       Impact factor: 4.406

Review 4.  Infectious complications of bone marrow transplantation.

Authors:  D J Winston; W G Ho; R E Champlin; R P Gale
Journal:  Exp Hematol       Date:  1984-03       Impact factor: 3.084

5.  Allogeneic marrow transplantation for acute lymphoblastic leukemia in remission using fractionated total body irradiation.

Authors:  R A Clift; C D Buckner; E D Thomas; J E Sanders; P S Stewart; R McGuffin; J Hersman; K M Sullivan; G E Sale; R Storb
Journal:  Leuk Res       Date:  1982       Impact factor: 3.156

6.  Protective environment for marrow transplant recipients: a prospective study.

Authors:  C D Buckner; R A Clift; J E Sanders; J D Meyers; G W Counts; V T Farewell; E D Thomas
Journal:  Ann Intern Med       Date:  1978-12       Impact factor: 25.391

7.  Effects of in vitro depletion of T cells in HLA-identical allogeneic marrow grafts.

Authors:  P J Martin; J A Hansen; C D Buckner; J E Sanders; H J Deeg; P Stewart; F R Appelbaum; R Clift; A Fefer; R P Witherspoon
Journal:  Blood       Date:  1985-09       Impact factor: 22.113

8.  Early infectious complications in allogeneic marrow transplant recipients with acute leukemia: effects of prophylactic measures.

Authors:  C D Buckner; R A Clift; E D Thomas; J Hersman; J E Sanders; P S Stewart; J C Wade; M Murphy; G Counts; J D Meyers
Journal:  Infection       Date:  1983 Sep-Oct       Impact factor: 3.553

9.  Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia.

Authors:  R Storb; H J Deeg; J Whitehead; F Appelbaum; P Beatty; W Bensinger; C D Buckner; R Clift; K Doney; V Farewell
Journal:  N Engl J Med       Date:  1986-03-20       Impact factor: 91.245

10.  Hickman catheter complications in marrow transplant recipients.

Authors:  F B Petersen; R A Clift; R O Hickman; J E Sanders; J D Meyers; J Kelleher; C D Buckner
Journal:  JPEN J Parenter Enteral Nutr       Date:  1986 Jan-Feb       Impact factor: 4.016

View more
  7 in total

1.  Fluoroquinolone prophylaxis in autologous hematopoietic stem cell transplant recipients.

Authors:  Dipenkumar Modi; Hyejeong Jang; Seongho Kim; Malini Surapaneni; Kamya Sankar; Abhinav Deol; Lois Ayash; Divaya Bhutani; Lawrence G Lum; Voravit Ratanatharathorn; Richard Manasa; Kendra Mellert; Pranatharthi Chandrasekar; Joseph P Uberti
Journal:  Support Care Cancer       Date:  2017-04-02       Impact factor: 3.603

2.  Outpatient management following intensive induction chemotherapy for myelodysplastic syndromes and acute myeloid leukemia: a pilot study.

Authors:  Roland B Walter; Stephanie J Lee; Kelda M Gardner; Xiaoyu Chai; Kathleen Shannon-Dorcy; Frederick R Appelbaum; Elihu H Estey
Journal:  Haematologica       Date:  2011-03-10       Impact factor: 9.941

3.  Outpatient intensive induction chemotherapy for acute myeloid leukemia and high-risk myelodysplastic syndrome.

Authors:  Frances Linzee Mabrey; Kelda M Gardner; Kathleen Shannon Dorcy; Andrea Perdue; Heather A Smith; Alicyn M Davis; Cody Hammer; Donelle Rizzuto; Sunny Jones; Kim Quach; Bart L Scott; Paul C Hendrie; Mary-Elizabeth M Percival; Roland B Walter; Frederick R Appelbaum; Elihu H Estey; Pamela S Becker
Journal:  Blood Adv       Date:  2020-02-25

Review 4.  Reduction in transplant-related complications in patients given intravenous immuno globulin after allogeneic marrow transplantation.

Authors:  M F Siadak; K Kopecky; K M Sullivan
Journal:  Clin Exp Immunol       Date:  1994-07       Impact factor: 4.330

5.  The impact of a change in antibacterial prophylaxis from ceftazidime to levofloxacin in allogeneic hematopoietic cell transplantation.

Authors:  K A Guthrie; M Yong; D Frieze; L Corey; D N Fredricks
Journal:  Bone Marrow Transplant       Date:  2009-08-31       Impact factor: 5.483

Review 6.  Prophylactic antibiotics or G(M)-CSF for the prevention of infections and improvement of survival in cancer patients receiving myelotoxic chemotherapy.

Authors:  Nicole Skoetz; Julia Bohlius; Andreas Engert; Ina Monsef; Oliver Blank; Jörg-Janne Vehreschild
Journal:  Cochrane Database Syst Rev       Date:  2015-12-21

7.  The use of intravenous antibiotics at the onset of neutropenia in patients receiving outpatient-based hematopoietic stem cell transplants.

Authors:  Aziz Hamadah; Yoko Schreiber; Baldwin Toye; Sheryl McDiarmid; Lothar Huebsch; Christopher Bredeson; Jason Tay
Journal:  PLoS One       Date:  2012-09-28       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.